~~<i id='5A6C4AFD5D'><strike id='5A6C4AFD5D'><tt id='5A6C4AFD5D'><pre id='5A6C4AFD5D'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：focus 2025-08-07 16:15:28 Page View：385

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

How faith leaders like me can help address America's obesity epidemic

AdobeManyfactorsdriveAmerica’sobesityepidemic—environment,genetics,eatinghabits,andmore.Solvingthepr

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

AdobeDiagnosticerrors—thatis,overlookingadisease,ordiagnosingiterroneouslyorlate—areaknownoccurrence